NEW YORK (GenomeWeb) – HTG Molecular Diagnostics said in a regulatory filing this week that it aims to raise $800,000 through a private offering of stock.
The Tucson, Ariz.-based firm declined to comment on the financing, but in a document filed with the US Securities and Exchange Commission, it said that there are two investors in the round, which comprised an option, warrant, or other right to acquire another security, as well as security to be acquired upon the exercise of an option, warrant, or other right to acquire security.
The investors were not named and HTG Molecular did not say how the proceeds would be used.
The company last week said that it had secured a $16 million debt facility. In February, HTG Molecular said that it initially closed its Series E preferred stock offering for an undisclosed amount.